Attributes for Max DiffRemission at 36 and 48 weeksAccrued duration of remission during 52 weeksTime to first relapseReduction of oral glucocorticoid dose during weeks 48 to 52Composite clinical improvementComplete responseACQ-6 (Asthma Control Questionnaire) response during weeks 48 to 52Safety / tolerabilityDosing and formulationDeplete blood eosinophilRemission – defined as a BVAS = 0 and OCS dose ≤4 mg/dayComposite clinical improvement – defined by reaching remission at any time during the study period, or with a ≥50% reduction in oral glucocorticoid dose during weeks 48-52, or no relapses of EGPA during the study period